Literature DB >> 25132267

Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells.

Q Cai1, L Yan1, Y Xu1.   

Abstract

High-grade serous ovarian cancer is an aggressive form of epithelial ovarian cancer (EOC), and accounts for the majority of deaths due to EOC. The critical cellular processes and underlying molecular mechanisms that define this malignancy remain poorly understood. Using a syngeneic murine model, we investigated the changes that accompanied the progression to increased aggressiveness induced by in vivo passage of mouse EOC cells. We found that enhanced anoikis resistance was a key cellular process associated with greater aggressiveness and tumorigenicity in vivo. Biochemical studies revealed that the enhanced anoikis resistance was associated with the activation of the Src/Akt/Erk signaling pathway. A higher rate of metabolism and autophagy were also associated with increased anoikis resistance. Blocking these pathways with specific inhibitors and/or genetic modifications significantly increased anoikis in vitro and inhibited tumor development in vivo. In addition, we demonstrated that similar signaling pathways were also involved in a human EOC cell line model. Collectively, our data suggest that anoikis resistance represents a critical and a distinguishing feature underlying the aggressiveness of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25132267      PMCID: PMC4333142          DOI: 10.1038/onc.2014.264

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  Anoikis: a necessary death program for anchorage-dependent cells.

Authors:  Paola Chiarugi; Elisa Giannoni
Journal:  Biochem Pharmacol       Date:  2008-07-25       Impact factor: 5.858

2.  Overcoming anoikis--pathways to anchorage-independent growth in cancer.

Authors:  Marta C Guadamillas; Ana Cerezo; Miguel A Del Pozo
Journal:  J Cell Sci       Date:  2011-10-01       Impact factor: 5.285

Review 3.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

4.  Development of a syngeneic mouse model for events related to ovarian cancer.

Authors:  K F Roby; C C Taylor; J P Sweetwood; Y Cheng; J L Pace; O Tawfik; D L Persons; P G Smith; P F Terranova
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

5.  Combination of local, non-viral IL12 gene therapy and systemic paclitaxel chemotherapy in a syngeneic ID8 mouse model for human ovarian cancer.

Authors:  Margit Maria Janát-Amsbury; James William Yockman; Matthew Linley Anderson; Dirk Günter Kieback; Sung Wan Kim
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

6.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.

Authors:  Zachary T Schafer; Alexandra R Grassian; Loling Song; Zhenyang Jiang; Zachary Gerhart-Hines; Hanna Y Irie; Sizhen Gao; Pere Puigserver; Joan S Brugge
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

7.  Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice.

Authors:  Hui Li; Dongmei Wang; Hong Zhang; Kashif Kirmani; Zhenwen Zhao; Rosemary Steinmetz; Yan Xu
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

8.  Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis.

Authors:  Ifat Sher; Sirin A Adham; James Petrik; Brenda L Coomber
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

Review 10.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

View more
  47 in total

1.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

2.  Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles.

Authors:  Marlies Cortés; Lidia Sanchez-Moral; Oriol de Barrios; María J Fernández-Aceñero; M C Martínez-Campanario; Anna Esteve-Codina; Douglas S Darling; Balázs Győrffy; Toby Lawrence; Douglas C Dean; Antonio Postigo
Journal:  EMBO J       Date:  2017-10-16       Impact factor: 11.598

3.  Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease.

Authors:  James L Chen; Jason David; Douglas Cook-Spaeth; Sydney Casey; David Cohen; Karuppaiyah Selvendiran; Tanios Bekaii-Saab; John L Hays
Journal:  Mol Cancer Res       Date:  2016-11-02       Impact factor: 5.852

Review 4.  Autophagy in malignant transformation and cancer progression.

Authors:  Lorenzo Galluzzi; Federico Pietrocola; José Manuel Bravo-San Pedro; Ravi K Amaravadi; Eric H Baehrecke; Francesco Cecconi; Patrice Codogno; Jayanta Debnath; David A Gewirtz; Vassiliki Karantza; Alec Kimmelman; Sharad Kumar; Beth Levine; Maria Chiara Maiuri; Seamus J Martin; Josef Penninger; Mauro Piacentini; David C Rubinsztein; Hans-Uwe Simon; Anne Simonsen; Andrew M Thorburn; Guillermo Velasco; Kevin M Ryan; Guido Kroemer
Journal:  EMBO J       Date:  2015-02-23       Impact factor: 11.598

5.  PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance.

Authors:  Kevin Tabury; Mehri Monavarian; Eduardo Listik; Abigail K Shelton; Alex Seok Choi; Roel Quintens; Rebecca C Arend; Nadine Hempel; C Ryan Miller; Balázs Györrfy; Karthikeyan Mythreye
Journal:  Life Sci Alliance       Date:  2022-07-12

6.  The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines.

Authors:  Zhenwen Zhao; Qingchun Cai; Yan Xu
Journal:  Lipids       Date:  2015-12-10       Impact factor: 1.880

7.  Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.

Authors:  Soochi Kim; Youngjin Han; Se Ik Kim; Juwon Lee; HyunA Jo; Wenyu Wang; Untack Cho; Woong-Yang Park; Thomas A Rando; Danny N Dhanasekaran; Yong Sang Song
Journal:  Mol Carcinog       Date:  2021-03-15       Impact factor: 4.784

Review 8.  Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing.

Authors:  Vinod S Bisht; Kuldeep Giri; Deepak Kumar; Kiran Ambatipudi
Journal:  Cancer Biol Ther       Date:  2021-10-25       Impact factor: 4.742

Review 9.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Stuart A Aaronson; John M Abrams; Dieter Adam; Patrizia Agostinis; Emad S Alnemri; Lucia Altucci; Ivano Amelio; David W Andrews; Margherita Annicchiarico-Petruzzelli; Alexey V Antonov; Eli Arama; Eric H Baehrecke; Nickolai A Barlev; Nicolas G Bazan; Francesca Bernassola; Mathieu J M Bertrand; Katiuscia Bianchi; Mikhail V Blagosklonny; Klas Blomgren; Christoph Borner; Patricia Boya; Catherine Brenner; Michelangelo Campanella; Eleonora Candi; Didac Carmona-Gutierrez; Francesco Cecconi; Francis K-M Chan; Navdeep S Chandel; Emily H Cheng; Jerry E Chipuk; John A Cidlowski; Aaron Ciechanover; Gerald M Cohen; Marcus Conrad; Juan R Cubillos-Ruiz; Peter E Czabotar; Vincenzo D'Angiolella; Ted M Dawson; Valina L Dawson; Vincenzo De Laurenzi; Ruggero De Maria; Klaus-Michael Debatin; Ralph J DeBerardinis; Mohanish Deshmukh; Nicola Di Daniele; Francesco Di Virgilio; Vishva M Dixit; Scott J Dixon; Colin S Duckett; Brian D Dynlacht; Wafik S El-Deiry; John W Elrod; Gian Maria Fimia; Simone Fulda; Ana J García-Sáez; Abhishek D Garg; Carmen Garrido; Evripidis Gavathiotis; Pierre Golstein; Eyal Gottlieb; Douglas R Green; Lloyd A Greene; Hinrich Gronemeyer; Atan Gross; Gyorgy Hajnoczky; J Marie Hardwick; Isaac S Harris; Michael O Hengartner; Claudio Hetz; Hidenori Ichijo; Marja Jäättelä; Bertrand Joseph; Philipp J Jost; Philippe P Juin; William J Kaiser; Michael Karin; Thomas Kaufmann; Oliver Kepp; Adi Kimchi; Richard N Kitsis; Daniel J Klionsky; Richard A Knight; Sharad Kumar; Sam W Lee; John J Lemasters; Beth Levine; Andreas Linkermann; Stuart A Lipton; Richard A Lockshin; Carlos López-Otín; Scott W Lowe; Tom Luedde; Enrico Lugli; Marion MacFarlane; Frank Madeo; Michal Malewicz; Walter Malorni; Gwenola Manic; Jean-Christophe Marine; Seamus J Martin; Jean-Claude Martinou; Jan Paul Medema; Patrick Mehlen; Pascal Meier; Sonia Melino; Edward A Miao; Jeffery D Molkentin; Ute M Moll; Cristina Muñoz-Pinedo; Shigekazu Nagata; Gabriel Nuñez; Andrew Oberst; Moshe Oren; Michael Overholtzer; Michele Pagano; Theocharis Panaretakis; Manolis Pasparakis; Josef M Penninger; David M Pereira; Shazib Pervaiz; Marcus E Peter; Mauro Piacentini; Paolo Pinton; Jochen H M Prehn; Hamsa Puthalakath; Gabriel A Rabinovich; Markus Rehm; Rosario Rizzuto; Cecilia M P Rodrigues; David C Rubinsztein; Thomas Rudel; Kevin M Ryan; Emre Sayan; Luca Scorrano; Feng Shao; Yufang Shi; John Silke; Hans-Uwe Simon; Antonella Sistigu; Brent R Stockwell; Andreas Strasser; Gyorgy Szabadkai; Stephen W G Tait; Daolin Tang; Nektarios Tavernarakis; Andrew Thorburn; Yoshihide Tsujimoto; Boris Turk; Tom Vanden Berghe; Peter Vandenabeele; Matthew G Vander Heiden; Andreas Villunger; Herbert W Virgin; Karen H Vousden; Domagoj Vucic; Erwin F Wagner; Henning Walczak; David Wallach; Ying Wang; James A Wells; Will Wood; Junying Yuan; Zahra Zakeri; Boris Zhivotovsky; Laurence Zitvogel; Gerry Melino; Guido Kroemer
Journal:  Cell Death Differ       Date:  2018-01-23       Impact factor: 12.067

Review 10.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.